Skip to content

Evaluation of topical Costus sp. preparation efficacy in treatment of neuropathy in cancer patients

Evaluation of topical Costus sp. preparation efficacy in treatment of taxane induced peripheral neuropathy in cancer patients : a pilot study and a randomised controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20131218015860N5
Enrollment
50
Registered
2019-03-10
Start date
2017-11-22
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplastic (malignant) related neuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: cancer patients with taxane induced peripheral neuropathy, receiving ointment of Coctus sp, 1 mg three times daily for four weeks. Intervention 2: Control group: ca

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with cancer Patients undergoing chemotherapy or Complete chemotherapy in the last two months Patients with complained of neuropathy whose neuropathy is due to chemotherapy with taxane drugs Having symptoms of peripheral neuropathy in all four organs Having at least B grade based on the PNQ questionnaire Having at least 18 years and maximum 80 years

Exclusion criteria

Exclusion criteria: diabetes renal failure Brain metastasis Carpal tunnel syndrome

Design outcomes

Primary

MeasureTime frame
Severity of neuropathy based on patient's statements. Timepoint: 14, 21 and 28 days after interference. Method of measurement: Neuropathy Severity Scale questionnaire.

Secondary

MeasureTime frame
Score of "The Cancer Neuropathy Scale". Timepoint: The weeks of 0 and 4 after treatment. Method of measurement: The Cancer neuropathy Scale questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghazaleh Heydarirad

Shahid Beheshti University of Medical Sciences

ghazalrad@yahoo.com+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026